Well Q let's hear the LuPIN trial interim data presented by...

Well Q let's hear the LuPIN trial interim data presented by Professor Emmett mid-February at ASCO.

Refer to RBx's comment titled LuPIN, and dated 18/12/19.

Additionally, the company demonstrates a strong commitment to shareholder-friendly management practice. There is never any shortage of presentations to keep investors up to date. The company's future focus is well explained.

I also like how management is going about de-risking shareholder investment. The creation and further listing of Nyrada being a perfect example.

I remain open to the idea that a single piece of news could propel Noxopharm into the ASX and media spotlight. But at the very least, one would hope that Professor Emmett will deliver further scientific evidence that continues to lay an enduring foundation for a prosperous future.